Solange Peters

Solange Peters

UNVERIFIED PROFILE

Are you Solange Peters?   Register this Author

Register author
Solange Peters

Solange Peters

Publications by authors named "Solange Peters"

Are you Solange Peters?   Register this Author

100Publications

2016Reads

-Profile Views

Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer.

Clin Cancer Res 2019 May 14;25(9):2691-2698. Epub 2019 Jan 14.

Research & Development, MedImmune, Gaithersburg, Maryland.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-3904DOI Listing
May 2019

De sérieuses préoccupations qui ne cachent pas nos espoirs.

Rev Med Suisse 2019 May;15(651):999-1000

Département d'oncologie, HUG, Genève.

View Article

Download full-text PDF

Source
May 2019

[The new management options for lung cancer in the immunotherapy era].

Rev Med Suisse 2019 May;15(651):1032-1037

Direction oncologie médicale, CHUV, BH 07, 1011 Lausanne.

View Article

Download full-text PDF

Source
May 2019

How to Make the Best Use of Immunotherapy as First-Line Treatment for Advanced/Metastatic Non-Small-Cell Lung Cancer.

Ann Oncol 2019 Mar 26. Epub 2019 Mar 26.

Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, and Parker Center for Cancer Immunotherapy, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz109DOI Listing
March 2019

Characterisation of rare haematological immune-related toxicities.

Lancet Haematol 2019 Jan 4;6(1):e10-e11. Epub 2018 Dec 4.

Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(18)30180-7DOI Listing
January 2019

New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.

Lancet Oncol 2019 Jan;20(1):e54-e64

Service Immunologie et Allergie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Centre d'Immunothérapie et de Vaccinologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Faculté Médecine Paris Descartes, Université Paris Descartes, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045183082
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(18)30828-3DOI Listing
January 2019

[Oncology, what's new in 2018].

Rev Med Suisse 2019 Jan;15(N° 632-633):78-81

Service d'oncologie médicale, Département d'oncologie, CHUV, 1011 Lausanne.

View Article

Download full-text PDF

Source
January 2019

Brain metastases.

Nat Rev Dis Primers 2019 Jan 17;5(1). Epub 2019 Jan 17.

Department of Neurosurgery, University of California-Davis, School of Medicine, Sacramento, CA, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41572-018-0055-y
Publisher Site
http://dx.doi.org/10.1038/s41572-018-0055-yDOI Listing
January 2019

Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program.

J Thorac Oncol 2018 Dec 7;13(12):1897-1905. Epub 2018 Aug 7.

Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan; and the Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.07.093DOI Listing
December 2018

Acceptance of the Advanced Practice Nurse in Lung Cancer Role by Healthcare Professionals and Patients: A Qualitative Exploration.

J Nurs Scholarsh 2018 Sep 22;50(5):540-548. Epub 2018 Jul 22.

Institute of Higher Education and Research in Healthcare, Faculty of Biology and Medicine, University of Lausanne, and Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jnu.12411DOI Listing
September 2018

Delineating the Role of PD-1/PD-L1 Blockade in Advanced SCLC.

J Thorac Oncol 2018 09;13(9):1242-1244

Oncology Department, Lausanne University Hospital, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183077
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.05.042DOI Listing
September 2018

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.

J Clin Oncol 2018 May 7:JCO2018782292. Epub 2018 May 7.

Jeremy Lewin and Lillian L. Siu, Princess Margaret Cancer Center, Toronto, Ontario, Canada; Jean-Charles Soria and Christophe Massard, Institut Gustave Roussy and University Paris-Sud, Villejuif; Jean-Pierre Delord, Institut Claudius Regaud Oncopole, Toulouse; Mohamed Bekradda, Oncology Therapeutic Development, Clichy; Keyvan Rezai, Hôpital René Huguenin, Saint-Cloud, France; Anastasios Stathis, Oncology Institute of Southern Switzerland, Bellinzona; Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Ahmad Awada and Philippe G. Aftimos, Université Libre de Bruxelles, Brussels, Belgium; and Zhen Zeng, Azher Hussain, and Susan Perez, Merck & Co, Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.2292DOI Listing
May 2018

Genomic Features of Response to Combination Immunotherapy in Lung Cancer.

Cancer Cell 2018 05;33(5):791-793

Department of Medical Oncology, University Hospital of Lausanne (CHUV), 1011 Lausanne, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108183017
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2018.04.005DOI Listing
May 2018

De vrais espoirs et de sérieuses préoccupations.

Rev Med Suisse 2018 May;14(607):1011-1012

Genolier Cancer Center, Clinique de Genolier.

View Article

Download full-text PDF

Source
May 2018

Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.

Curr Treat Options Oncol 2018 05 28;19(7):37. Epub 2018 May 28.

Oncology Department, Centre Hospitalier Universitaire Vaudois, BH09/725, Rue du Bugnon 46, 1000, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0553-xDOI Listing
May 2018

Immune Checkpoint Inhibitors in the Management of Lung Cancer.

Am Soc Clin Oncol Educ Book 2018 May;38:682-695

From the Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA; and the Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_201319DOI Listing
May 2018

EML4-ALK Variant Affects ALK Resistance Mutations.

J Clin Oncol 2018 Apr 1;36(12):1257-1259. Epub 2018 Mar 1.

Martin Früh, Cantonal Hospital of St Gallen, St Gallen, Switzerland; and Solange Peters, University Hospital of Lausanne, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.2764DOI Listing
April 2018

RANKL Signaling Sustains Primary Tumor Growth in Genetically Engineered Mouse Models of Lung Adenocarcinoma.

J Thorac Oncol 2018 03 6;13(3):387-398. Epub 2017 Dec 6.

Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.11.121DOI Listing
March 2018

PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.

Cancer Treat Rev 2018 Jan 23;62:39-49. Epub 2017 Oct 23.

Department of Oncology, University Hospital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.10.002DOI Listing
January 2018

Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer.

N Engl J Med 2017 11;377(20):1986-1988

From Columbia University Medical Center, New York (N.A.R.); and Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (S.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1711430DOI Listing
November 2017

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

N Engl J Med 2017 08 6;377(9):829-838. Epub 2017 Jun 6.

From Lausanne University Hospital, Lausanne (S.P.), and F. Hoffmann-La Roche, Basel (A.Z., E.M., S. Golding, B.B., J.N.) - both in Switzerland; University of Colorado, Denver (D.R.C.); Massachusetts General Hospital, Boston (A.T.S.); University of Michigan, Ann Arbor (S. Gadgeel); Samsung Medical Center, Sungkyunkwan University School of Medicine (J.S.A.), and Seoul National University Hospital (D.-W.K.) - both in Seoul, South Korea; Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (S.-H.I.O.); Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France (M.P.); Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland (R.D.); Catalan Institute of Oncology, Barcelona (R.R.); Roche Innovation Center, New York (P.N.M.); and State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong (T.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1704795DOI Listing
August 2017

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

J Clin Oncol 2017 Aug 13;35(24):2781-2789. Epub 2017 Jun 13.

Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne; Martin Früh, Kantonsspital St Gallen, St Gallen, Switzerland; Scott Gettinger, Yale Cancer Center, New Haven, CT; Melissa L. Johnson, Sarah Cannon Research Institute, Nashville, TN; Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA; Marina C. Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Daniel Christoph, Universitätsklinikum Essen, and the Ruhrlandklinik, Universität Duisburg-Essen, Essen; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany; Chee Keong Toh, National Cancer Centre, Singapore, Singapore; Naiyer A. Rizvi and Jamie E. Chaft, Memorial Sloan Kettering Cancer Center; Jamie E. Chaft, Weill Cornell Medical College, New York, NY; Enric Carcereny Costa, Catalan Institute of Oncology Badalona, Badalona; Luis Paz-Ares, Hospital Universitario Doce de Octubre & IIS i+12, CNIO, Ciberonc and Universidad Complutense, Madrid; Enriqueta Felip, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Jyoti D. Patel, University of Chicago, Chicago, IL; Laura Q.M. Chow, University of Washington, Seattle, WA; Marianna Koczywas, City of Hope, Duarte; Zhengrong Li, Jiaheng Qiu, Marcin Kowanetz, Simonetta Mocci, Geetha Shankar, and Alan Sandler, Genentech, South San Francisco, CA; Cheryl Ho, Vancouver Centre, BC Cancer Agency, Vancouver, British Columbia; Jeffrey Rothenstein, R.S. McLaughlin Durham Regional Cancer Centre, Oshawa; Frances A. Shepherd, Princess Margaret Cancer Centre/University Health Network and University of Toronto, Toronto, Ontario, Canada; Michel van den Heuvel, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; and Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.9476DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562171PMC
August 2017

Feasibility of advanced practice nursing in lung cancer consultations during early treatment: A phase II study.

Eur J Oncol Nurs 2017 Aug 12;29:106-114. Epub 2017 Jun 12.

Institute of Higher Education and Research in Healthcare, Faculty of Biology and Medicine, University of Lausanne and Lausanne University Hospital, Switzerland; Department of Oncology, Lausanne University Hospital, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejon.2017.05.007DOI Listing
August 2017

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

N Engl J Med 2017 06;376(25):2415-2426

From the Ohio State University Comprehensive Cancer Center, Columbus (D.P.C.); LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.), and Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) - both in Germany; Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas and Universidad Complutense, Madrid (L.P.-A., J.C.J.), Vall d'Hebron University Hospital, Barcelona (E.F.), and Hospital Universitario Insular de Gran Canaria, Las Palmas (D.R.-A.) - all in Spain; H. Lee Moffitt Cancer Center, Tampa, FL (B.C.); Vanderbilt University Medical Center, Nashville (L. Horn); Antoni van Leeuwenhoek Ziekenhuis, Amsterdam (M.M.H.), and University of Groningen, Universitair Medisch Centrum Groningen, Groningen (T.J.N.H.) - both in the Netherlands; Prof. Dr. Ion Chiricuta Institute of Oncology and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.); Baptist Health Lexington, Lexington, KY (F.B.); Duke University, Durham, NC (N.R.); Lehigh Valley Health Network, Allentown (S.N.), Fox Chase Cancer Center, Philadelphia (H.B.), and University of Pittsburgh Medical Center Cancer Center, Pittsburgh (L.C.V., M.A.S.) - all in Pennsylvania; Juravinski Cancer Centre, Hamilton, ON, Canada (R.J.); Oncology Department, Lausanne University Hospital, Lausanne, Switzerland (S.P.); Santa Maria Hospital, Terni, Italy (E.M.); Hollings Cancer Center, Charleston, SC (J.M.W.); Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.); Klinika Pneumologie a Hrudní Chirurgie, Nemocnice Na Bulovce, Prague, Czech Republic (L. Havel, J.K.); and Bristol-Myers Squibb, Princeton, NJ (H.C., W.J.G., P.B., A.C.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1613493DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487310PMC
June 2017

L’accès à l’innovation.

Rev Med Suisse 2017 May;13(563):1027

Département d'oncologie, CHUV, Lausanne.

View Article

Download full-text PDF

Source
May 2017

Seeking New Approaches to Patients With Small Cell Lung Cancer.

Am Soc Clin Oncol Educ Book 2016 ;35:e477-82

From the Merck Research Laboratories, Rahway, NJ; Department of Oncology, HFR Fribourg, Fribourg, Switzerland; Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Winship Cancer Institute of Emory University, Atlanta, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_158710DOI Listing
January 2017

Investigating Barriers in HIV-Testing Oncology Patients: The IBITOP Study, Phase I.

Oncologist 2016 10 20;21(10):1176-1182. Epub 2016 Jul 20.

Infectious Diseases Service, Department of Medicine, Lausanne University Hospital, Lausanne, Switzerland

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2016-0107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061530PMC
October 2016

The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer.

Cancer Treat Rev 2016 Apr 15;45:139-62. Epub 2016 Mar 15.

Princess Margaret Hospital/University Health Network, 610 University Avenue, Toronto M5G 2M9, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2016.03.009DOI Listing
April 2016

Emerging Options After Progression During Crizotinib Therapy.

Authors:
Solange Peters

J Clin Oncol 2016 Mar 28;34(7):643-5. Epub 2015 Dec 28.

Lausanne University Hospital, Lausanne, Switzerland

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.1406DOI Listing
March 2016

Investigating barriers in HIV-testing oncology patients. The IBITOP study: phase I.

J Int AIDS Soc 2014 2;17(4 Suppl 3):19622. Epub 2014 Nov 2.

Service of Infectious Diseases, Lausanne University Hospital, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224909PMC
http://dx.doi.org/10.7448/IAS.17.4.19622DOI Listing
January 2016

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.

J Thorac Oncol 2015 Oct;10(10):1451-7

*Tumorzentrum, Luzerner Kantonsspital, Luzern, Switzerland; †Hôpital Larrey, Centre Hospital-Universitaire, Université Paul Sabatier, Toulouse, France; ‡Institut Claudius Regaud IUCT-O, Toulouse, France; §Institut Gustave Roussy, Villejuif, France; ¶VU University Medical Center, Amsterdam, The Netherlands; ‖Center of Integrated Oncology Cologne, University Hospital Cologne, Cologne, Germany; #Centre Pluridisciplinaire d'Oncologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; **Onkologie/Hämatologie, Kantonsspital St. Gallen, St. Gallen, Switzerland; ††Medizinische Klinik, St. Claraspital, Basel, Switzerland; ‡‡Service de pneumologie et oncologie thoracique, Hopital Universitaire, Caen, France; §§University Hospital Essen, Essen, Germany; ¶¶University Hospital Zurich, Zurich, Switzerland; ‖‖Clinique Teissier, Valenciennes, France; ##Centre Hospitalier Intercommunal de Creteil, Créteil, France; ***University Hospital Innsbruck, Innsbruck, Austria; †††University Hospital Basel, Basel, Switzerland; ‡‡‡Heidelberg University Medical Center, Mannheim, Germany; §§§Hopital du Haut Lévèque, Pessac, France; ¶¶¶Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; and ‖‖‖Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000625DOI Listing
October 2015

BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.

J Thorac Oncol 2015 Oct;10(10):1396-403

*Service d'oncologie médicale, Département d'oncologie, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; and †Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000644DOI Listing
October 2015

[Is prescription of a therapy costing 150,000 CHF reasonable?].

Rev Med Suisse 2015 Oct;11(491):1967-72

View Article

Download full-text PDF

Source
October 2015

Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer.

Cancer Metastasis Rev 2015 Jun;34(2):173-82

Department of Oncology, HFR Fribourg-Hôpital Cantonal, CH-1708, Fribourg, Switzerland,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-015-9560-6DOI Listing
June 2015

Lung cancer. How much platinum-based chemotherapy is enough in NSCLC?

Nat Rev Clin Oncol 2015 Jan 2;12(1):8-10. Epub 2014 Dec 2.

Roswell Park Cancer Institute, Elm &Carlton Streets, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2014.212DOI Listing
January 2015

Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters.

J Thorac Oncol 2014 Nov;9(11):1675-84

*Centre Hospitalier Universitaire de Vaud, Lausanne, Switzerland; †Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland; ‡Frontier Science Foundation-Hellas & University of Athens, Athens, Greece; §Aberdeen Royal Infirmary, Aberdeen, United Kingdom; ‖Institute for Pathology, University Hospital Basel, Basel, Switzerland; ¶Department of Oncology, University Hospital, Aarhus, Denmark; #Department of Medical Oncology, St. James's Hospital, Dublin, Ireland; **Medical University of Gdansk, Gdansk, Poland; ††University Hospital KU Leuven, Leuven, Belgium; ‡‡Vall d'Hebron University Hospital, Barcelona, Spain; §§Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; ‖‖Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; ¶¶VU University Medical Center, Amsterdam, Netherlands; ##Maastricht University Medical Centre, Maastricht, Netherlands; ***Manchester University and The Christie National Health Services Foundation Trust, Manchester, United Kingdom; †††Netherlands Cancer Institute, Amsterdam, Netherlands; ‡‡‡Department of Medicine, University of Valencia and Department of Medical Oncology, General University Hospital of Valencia, Valencia, Spain; §§§Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; and ‖‖‖Clinic of Oncology, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000320DOI Listing
November 2014

Pan-HER inhibition in EGFR wild-type non-small-cell lung cancer.

Lancet Oncol 2014 Nov 15;15(12):1289-90. Epub 2014 Oct 15.

VU University Medical Center, Amsterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(14)71027-7DOI Listing
November 2014

Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.

Melanoma Res 2014 Oct;24(5):496-500

Departments of aOncology bDermatology cPathology, CHUV, Lausanne dService of Hemato-Oncology, Department of Internal Medicine, Hospital of Fribourg, Fribourg, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000055DOI Listing
October 2014

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.

Cancer Treat Rev 2014 Sep 1;40(8):917-26. Epub 2014 Jul 1.

Department of Medicine, Katherine Anne Gioia Chair in Cancer Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2014.06.010DOI Listing
September 2014

Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.

J Clin Oncol 2014 Sep 28;32(25):2780-7. Epub 2014 Jul 28.

Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.5921DOI Listing
September 2014

Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases.

Cancer Treat Rev 2014 Jul 8;40(6):716-22. Epub 2014 Apr 8.

Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2014.03.005DOI Listing
July 2014

Targeted therapy in NSCLC driven by HER2 insertions.

Transl Lung Cancer Res 2014 Apr;3(2):84-8

Department of Oncology, University Hospital of Vaudois (CHUV), Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2014.02.06DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367663PMC
April 2014

ALK inhibitors in the treatment of advanced NSCLC.

Cancer Treat Rev 2014 Mar 7;40(2):300-6. Epub 2013 Aug 7.

Division of Medical Oncology, "S.G. Moscati" Hospital, Avellino, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2013.07.002DOI Listing
March 2014

Cerebral nocardiosis mimicking multiple brain metastases in a patient with locally advanced non-small-cell lung cancer.

J Thorac Oncol 2014 Mar;9(3):e24-6

*Infectious Diseases Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; †Oncology Department, Fribourg Hospital and Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne; Switzerland; ‡Roswell Park Cancer Institute, Buffalo, New York; §Radiology Department, ‖Microbiology Institute, and ¶Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000018DOI Listing
March 2014

Strategies for improving outcomes in NSCLC: a look to the future.

Lung Cancer 2013 Dec 8;82(3):375-82. Epub 2013 Sep 8.

Department of Oncology, University Hospital Zurich, Zurich, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2013.08.025DOI Listing
December 2013

Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.

Lung Cancer 2013 Nov 19;82(2):365-7. Epub 2013 Aug 19.

Department of Medical Oncology, Luzerner Kantonsspital, Luzern, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2013.08.012DOI Listing
November 2013

Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.

Clin Cancer Res 2013 Oct 15;19(20):5749-57. Epub 2013 Aug 15.

Authors' Affiliations: Department of Oncology, University Hospital of Lausanne; Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; Vital-IT, Swiss Institute of Bioinformatics, and the Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0661DOI Listing
October 2013

Practical tips and tricks with recently approved molecular targeted agents in non-small-cell lung cancer.

EJC Suppl 2013 Sep;11(2):307-9

Centre Hospitalier Universitaire Vaudois (CHUV), Oncology Department, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejcsup.2013.07.058DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041556PMC
September 2013

Treatment and detection of ALK-rearranged NSCLC.

Lung Cancer 2013 Aug 12;81(2):145-54. Epub 2013 Jun 12.

Department of Oncology, University Hospital of Vaudois (CHUV), Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2013.03.017DOI Listing
August 2013

Impact of induction therapy on airway complications after sleeve lobectomy for lung cancer.

Ann Thorac Surg 2013 Jul 16;96(1):247-52. Epub 2013 May 16.

Division of Thoracic Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2013.04.009DOI Listing
July 2013

Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.

J Clin Oncol 2013 Jul 3;31(20):e341-4. Epub 2013 Jun 3.

Centre Hospitalier Universitaire Vaudois, Oncology Department, CHUV BH06, Rue du Bugnon 46, 1011 Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.6143DOI Listing
July 2013

A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable?

Lung Cancer 2013 Apr 4;80(1):81-4. Epub 2013 Feb 4.

HFR Fribourg, Hôpital Cantonal, Department of Internal Medicine, Division of Oncology, Fribourg, Switzerland.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01695002120063
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2012.11.013DOI Listing
April 2013

Targeting receptor activator of nuclear factor-kappa B as a new therapy for bone metastasis in non-small cell lung cancer.

Curr Opin Oncol 2013 Mar;25(2):137-44

Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, and Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e32835d720bDOI Listing
March 2013

Therapeutic advances in non-small cell lung cancer.

Thorax 2012 Dec 5;67(12):1097-101. Epub 2011 Nov 5.

Department of Thoracic Surgery, Swedish Cancer Institute, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2011-2010
Publisher Site
http://dx.doi.org/10.1136/thoraxjnl-2011-201043DOI Listing
December 2012

Impact of lung function changes after induction radiochemotherapy on resected T4 non-small cell lung cancer outcome.

Ann Thorac Surg 2012 Dec 25;94(6):1815-22. Epub 2012 Oct 25.

Department of Thoracic and Vascular Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2012.08.054DOI Listing
December 2012

Pulmonary sarcoid-like granulomatosis induced by ipilimumab.

J Clin Oncol 2012 Jun 30;30(17):e156-9. Epub 2012 Apr 30.

Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.39.3298DOI Listing
June 2012

MET: a promising anticancer therapeutic target.

Nat Rev Clin Oncol 2012 May 8;9(6):314-26. Epub 2012 May 8.

Centre Pluridisciplinaire d'Oncologie, Centre Hospitalier Universitaire Vaudois (CHUV), Rue du Bugnon 46, CH1011 Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2012.71DOI Listing
May 2012

Photodynamic induced uptake of liposomal doxorubicin to rat lung tumors parallels tumor vascular density.

Lasers Surg Med 2012 Apr 23;44(4):318-24. Epub 2012 Feb 23.

Division of Thoracic and Vascular Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/lsm.22013DOI Listing
April 2012

Extrapleural pneumonectomy with venous confluence resection for stage IVA thymic tumors.

Ann Thorac Surg 2011 Mar;91(3):941-3

Thoracic and Vascular Surgery Service, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2010.07.048DOI Listing
March 2011

Trimodality therapy for locally advanced non-small-cell lung cancer: a curative approach.

J Clin Oncol 2011 Feb 4;29(5):e118-9; author reply e120. Epub 2011 Jan 4.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2010.30.1143DOI Listing
February 2011

Solitary choriocarcinoma in the lung.

J Thorac Oncol 2010 Apr;5(4):574-5

Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3181cbf372DOI Listing
April 2010

Thalidomide in small cell lung cancer: wrong drug or wrong disease?

J Natl Cancer Inst 2009 Aug 16;101(15):1034-5. Epub 2009 Jul 16.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djp208DOI Listing
August 2009